Leadership and Data Catalysts for Newron's Pivotal Schizophrenia Drug

Newron presents Evenamide data at SIRS congress, plans board refresh, and advances Phase III trials for treatment-resistant schizophrenia with €38M funding.

Italian biopharmaceutical firm Newron SpA is navigating a period of significant transition, marked by an impending board refresh and the presentation of key scientific data for its lead candidate, Evenamide. These developments come at a critical juncture as the company advances its late-stage clinical program.

Scientific Spotlight at SIRS Congress

The company is currently showcasing new findings for Evenamide at the Schizophrenia International Research Society (SIRS) congress in Florence, running from March 25 to 29. The presentations include preclinical data suggesting potential long-term clinical benefits for patients with treatment-resistant schizophrenia (TRS). Further poster updates on the Phase III ENIGMA-TRS program and patient social functionality data are scheduled for Friday and Saturday.

Evenamide is a first-in-class glutamate modulator. It is being developed as an adjunctive therapy for TRS patients, a condition that currently lacks any approved supplemental treatment options.

Governance Refresh on the Horizon

A shareholder meeting scheduled for April 23 will see changes to the company's supervisory board. Two long-tenured members, Patrick Langlois (18 years on the board) and Luca Benatti—a key figure in the development of the Parkinson's drug Xadago®—will not stand for re-election.

Their proposed successors are George Garibaldi and Paolo Zocchi, both nominated as independent non-executive directors. Garibaldi offers over three decades of experience in central nervous system (CNS) drug development and currently serves as Chief Medical Officer at Synendos Therapeutics. Zocchi brings more than 35 years of financial advisory expertise from his tenure as an International Senior Partner at Ernst & Young, where his client roster included industry giants Sanofi and Bayer.

Clinical and Financial Roadmap

Newron's pivotal Phase III trials for Evenamide are underway concurrently. The ENIGMA-TRS 1 study, initiated in August 2025, targets at least 600 patients over one year. Its counterpart, ENIGMA-TRS 2, began in December 2025 and has a 12-week duration. The company anticipates reporting primary endpoint results from ENIGMA-TRS 2 in the fourth quarter of 2026.

Financially, Newron has fortified its balance sheet to fund this crucial development path. In February 2026, it completed a capital raise of up to €38 million with support from existing and new investors across Europe and Asia. This bolstered liquidity despite a net loss of €13.2 million for the 2025 fiscal year, which followed a profitable prior period. In a further boost, the European Patent Office granted an additional substance patent for Evenamide, providing protection until 2044.

Market Sentiment and Analyst Attention

The equity has faced headwinds in the current year, declining approximately 40% in value since January. It currently trades just below its 200-day moving average, a level market observers suggest reflects prevailing uncertainty ahead of the decisive Phase III data. Notably, the investment case has recently attracted coverage initiations from four new analysts based in the United States and Europe, highlighting growing institutional interest in the upcoming clinical readouts.